Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649935 | Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg | PHASE1 | COMPLETED | 54 | — | — | May 1, 2005 | Jun 1, 2005 | Apr 24, 2024 | 1 | United States |
| NCT00650273 | Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg | PHASE1 | COMPLETED | 54 | — | — | Apr 1, 2005 | May 1, 2005 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Azithromycin Tablets 600 mg |
| 2 | ACTIVE_COMPARATOR | Zithromax® Tablets 600 mg |
| Name | Type | Description |
|---|---|---|
| Azithromycin Tablets 600 mg | DRUG | 600mg, single dose fed |
| Zithromax® Tablets 600 mg | DRUG | 600mg, single dose fed |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ...